The ADHD challenge

The core symp­toms of ADHD fre­quently cause sig­nif­i­cant impair­ment in aca­d­e­mic, social and behav­ioral func­tion­ing that adversely impact indi­vid­u­als’ qual­ity of life. These symp­toms often per­sist into adult­hood, poten­tially com­pro­mis­ing an individual’s func­tion­ing over many years. Under­stand­ing how ADHD impacts long-term func­tion­ing, and whether adverse long-term affects are dimin­ished with treat­ment, is Read the rest of this entry »

Just a quick heads-up to the Sharp­Brains com­mu­nity: we are wrap­ping up a com­pre­hen­sive mar­ket report on Per­va­sive Neu­rotech­nolo­gies (non-invasive, scal­able, poten­tially ubiq­ui­tous). To learn when it becomes avail­able, keep tuned via our e-Newsletter.

See below, in alpha­bet­i­cal order, a few of the orga­ni­za­tions to be pro­filed in the report, given their rel­e­vant intel­lec­tual prop­erty port­fo­lios (pri­mar­ily patents). Read the rest of this entry »

“Peo­ple have always wanted to find a way to assess someone’s cog­ni­tive and emo­tional traits in an objec­tive way that might give them a sense of: What is this per­son really ide­ally suited for?” she says.

“Thync bills itself first and fore­most as a neu­ro­science com­pany. Its sole product—slated for release later this year—is a smartphone-controlled wear­able device that will allow the user to actively alter his or her brain’s elec­tri­cal state through tran­scra­nial direct cur­rent stim­u­la­tion (tDCS). The big idea: Read the rest of this entry »

“One thing is clear: Pharma’s com­mit­ment to “beyond the pill” has never been so apparent.

Each and every pharma com­pany seems to have formed a divi­sion or a strate­gic team to explore new ser­vices around patient com­pli­ance, pop­u­la­tion health data and fur­ther­ing con­nec­tiv­ity for improv­ing patient man­age­ment… Read the rest of this entry »